Shilpa CDMO to Redefine Complex Drug Manufacturing at CPHI Milan Launch

Shilpa CDMO, a new specialist in complex small-molecule drug development and manufacturing, is set to officially launch next month at CPHI Milan, the global pharmaceutical exhibition taking place from October 6-8, 2026. This dedicated entity, spun off from parent company Shilpa Medicare, aims to provide biotech and pharma customers with crucial support for challenging new medicines, leveraging over 30 years of expertise, especially in oncology. The timing is no accident: the global CDMO market, projected to hit nearly $80 billion this year, is seeing a significant shift as US and European biotechnology companies actively seek to diversify their supply chains away from China. Shilpa CDMO, led by CEO Keshav Bhutada, is positioning itself to fill this 'capable capacity' gap, offering end-to-end services from discovery to commercial manufacturing for high-potency active pharmaceutical ingredients (HPAPIs), antibody-drug conjugates (ADCs), peptides, PROTACs, and oligonucleotides. Their integrated approach, including co-location with sister company Shilpa Biologicals for streamlined ADC development, underscores a strategic push into high-value, complex therapeutics. As CPHI Milan approaches, industry watchers will be keen to see the specific details of Shilpa CDMO expanded commercial-scale peptide manufacturing capabilities, which are also slated for announcement at the event. With substantial investments in manufacturing platforms, R&D centers, and scientific talent already in place, the company is poised to become a critical partner in speeding up the development of next-generation complex drugs, potentially shortening timelines and simplifying supply chains for global pharma innovators.